199 related articles for article (PubMed ID: 25829089)
1. PET/Computed Tomography and Patient Outcomes in Melanoma.
Rohren EM
PET Clin; 2015 Apr; 10(2):243-54. PubMed ID: 25829089
[TBL] [Abstract][Full Text] [Related]
2. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
Kwee RM; Marcus C; Sheikhbahaei S; Subramaniam RM
PET Clin; 2015 Apr; 10(2):197-205. PubMed ID: 25829086
[TBL] [Abstract][Full Text] [Related]
3. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
4. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.
Abbott RA; Acland KM; Harries M; O'Doherty M
Melanoma Res; 2011 Oct; 21(5):446-9. PubMed ID: 21849913
[TBL] [Abstract][Full Text] [Related]
5. Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer.
Ciarallo A; Marcus C; Taghipour M; Subramaniam RM
PET Clin; 2015 Apr; 10(2):265-78. PubMed ID: 25829091
[TBL] [Abstract][Full Text] [Related]
6. (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes.
Wray R; Solnes L; Mena E; Meoded A; Subramaniam RM
PET Clin; 2015 Jul; 10(3):423-30. PubMed ID: 26099676
[TBL] [Abstract][Full Text] [Related]
7. Outcome of clinical stage III melanoma patients with FDG-PET and whole-body CT added to the diagnostic workup.
Niebling MG; Bastiaannet E; Hoekstra OS; Bonenkamp JJ; Koelemij R; Hoekstra HJ
Ann Surg Oncol; 2013 Sep; 20(9):3098-105. PubMed ID: 23612885
[TBL] [Abstract][Full Text] [Related]
8. A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma.
Beasley GM; Parsons C; Broadwater G; Selim MA; Marzban S; Abernethy AP; Salama AK; Eikman EA; Wong T; Zager JS; Tyler DS
Ann Surg; 2012 Aug; 256(2):350-6. PubMed ID: 22691370
[TBL] [Abstract][Full Text] [Related]
9. 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma.
Wieder HA; Tekin G; Rosenbaum-Krumme S; Klode J; Altenbernd J; Bockisch A; Nagarajah J
Nuklearmedizin; 2013; 52(5):198-203. PubMed ID: 23969722
[TBL] [Abstract][Full Text] [Related]
10. Can (18)F-FDG PET/CT predict recurrence in patients with cutaneous malignant melanoma?
Kang S; Ahn BC; Hong CM; Song BI; Lee HJ; Jeong SY; Lee SW; Lee J; Lee SJ
Nuklearmedizin; 2011; 50(3):116-21. PubMed ID: 21246162
[TBL] [Abstract][Full Text] [Related]
11. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
12. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
13. [(18)F]Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) physiologic imaging of choroidal melanoma: before and after ophthalmic plaque radiation therapy.
Finger PT; Chin KJ
Int J Radiat Oncol Biol Phys; 2011 Jan; 79(1):137-42. PubMed ID: 20395070
[TBL] [Abstract][Full Text] [Related]
14. Fludeoxyglucose F 18 PET-Computed Tomography: Management Changes Effecting Patient Outcomes in Gynecologic Malignancies.
Brunetti JC
PET Clin; 2015 Jul; 10(3):395-409. PubMed ID: 26099674
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
[TBL] [Abstract][Full Text] [Related]
16. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.
Parikh U; Marcus C; Sarangi R; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):327-43. PubMed ID: 26099670
[TBL] [Abstract][Full Text] [Related]
17. Pediatric bone sarcoma: diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up.
Quartuccio N; Fox J; Kuk D; Wexler LH; Baldari S; Cistaro A; Schöder H
AJR Am J Roentgenol; 2015 Jan; 204(1):153-60. PubMed ID: 25539251
[TBL] [Abstract][Full Text] [Related]
18. Metastatic malignant melanoma to the thyroid gland detected by FDG-PET imaging.
Basu S; Alavi A
Clin Nucl Med; 2007 May; 32(5):388-9. PubMed ID: 17452870
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
[TBL] [Abstract][Full Text] [Related]
20. Commentary: Improved patient outcomes remain elusive after intensive imaging surveillance for high-risk melanoma.
Swetter SM
J Am Acad Dermatol; 2016 Sep; 75(3):525-527. PubMed ID: 27317056
[No Abstract] [Full Text] [Related]
[Next] [New Search]